Physician

Giancarlo A. Pillot, M.D.

According to 2025 Medicare claims, Giancarlo Pillot, M.D. (NPI: 1316994098) practices medical oncology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from St. Louis, MO. This provider's primary affiliated billing organization is ST. LOUIS CANCER CARE, L.L.P. (NPI: 1932156726; TIN: 431369550) and primary practice location at 63044-3432.

Pillot's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 210 traditional Medicare patients, billed 43,655 HCPCS/CPT codes, and received $1,198,024 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,084 prescription claims across 208 beneficiaries totaling $3,951,807 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 23 claims. Open Payments data shows 8 records totaling $1,885. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $993,213 to $3,951,807. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,968 and ending at $1,446.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	307	72,182	$1,151,976
2016	287	63,608	$1,059,439
2017	289	46,233	$637,577
2018	344	61,138	$1,520,081
2019	310	75,436	$1,357,223
2020	264	55,660	$1,264,477
2021	252	43,507	$1,124,251
2022	254	50,222	$1,063,799
2023	244	51,022	$1,256,468
2024	210	43,655	$1,198,024

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	168	932	$993,213
2016	165	920	$707,210
2017	170	773	$855,520
2018	222	1,176	$2,449,928
2019	226	1,382	$3,837,519
2020	227	1,169	$2,771,348
2021	229	1,183	$2,998,214
2022	227	1,110	$3,504,110
2023	215	1,087	$3,069,978
2024	208	1,084	$3,951,807

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	57	$1,456
2016	N/R	11	$201
2017	N/R	32	$753
2018	N/R	134	$11,444
2019	N/R	59	$8,738
2020	N/R	23	$2,345
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	88	244	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	78	99	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	77	98	$13
36415	Insertion of needle into vein for collection of blood sample	97	363	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	123	516	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	54	1,484	$906,007
Jakafi	Ruxolitinib Phosphate	37	1,110	$634,336
Calquence	Acalabrutinib Maleate	36	1,080	$540,354
Ibrance	Palbociclib	25	700	$398,344
Venclexta	Venetoclax	27	792	$331,772

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$1,885	Avyxa Pharma, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Giancarlo A. Pillot, M.D.?

Tedicare shows public-source Medicare data for Giancarlo A. Pillot, M.D. (NPI 1316994098), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Giancarlo A. Pillot, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Giancarlo A. Pillot, M.D.?

Giancarlo A. Pillot, M.D. is linked to ST. LOUIS CANCER CARE, L.L.P. (billing NPI 1932156726) in the available physician profile data.

Does Giancarlo A. Pillot, M.D. have Open Payments data?

Giancarlo A. Pillot, M.D. has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.